MyoKardia’s scientists have discovered a portfolio of small molecule therapeutics aimed at the muscle proteins of the heart and intended to correct the excessive contraction, impaired relaxation or insufficient contraction underlying diseases of systolic and diastolic dysfunction. We are applying a precision medicine approach to develop our therapeutic candidates for patient populations with shared characteristics, such as c...
MyoKardia’s scientists have discovered a portfolio of small molecule therapeutics aimed at the muscle proteins of the heart and intended to correct the excessive contraction, impaired relaxation or insufficient contraction underlying diseases of systolic and diastolic dysfunction. We are applying a precision medicine approach to develop our therapeutic candidates for patient populations with shared characteristics, such as causal genetic mutations or disease subtypes. Our clinical-stage pipeline includes: mavacamten (formerly 461) in Phase 3 and Phase 2 clinical trials for hypertrophic cardiomyopathies (HCM).
Upgrade this company profile// Update & customize all content. Ask PharmaCompass, click HERE.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
